A Trial of Camrelizumab Combined With Ablation and Chemotherapy in Patients With Pancreatic Cancer Liver Metastasis（SHR-1210-HLJ-009）

Camrelizumab Combined With Ablation and Chemotherapy in Patients With Pancreatic Cancer Liver Metastasis: a Single-arm, Prospective Study

NCT04420130•Yanqiao Zhang

View on ClinicalTrials.gov

Summary

This is a a single-arm, prospective study of Camrelizumab combined with ablation and chemotherapy for patients with Pancreatic cancer liver metastasis. The main purpose of this study is to evaluate the safety and tolerability of Camrelizumab combined with ablation and chemotherapy as a treatment of Pancreatic cancer liver metastasis.

Eligibility

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients with liver metastasis of pancreatic cancer diagnosed by histology or cytology;
•Must have CT or MRI examination in the last 3 months;
•With measurable tumor lesions (spiral CT scan ≥10mm, meet RECIST 1.1 standard);
•Expected survival time\> 3 months;
•The interval between the end of the patient's previous chemotherapy or adjuvant chemotherapy must be more than 6 months;
•No radiation therapy (unless there is at least one measurable target lesion in the non-irradiated area);
•Must score pain;
•Age: 18 to 70 years old, male or female;
•ECOG PS: 0-1 points;
•The functions of important organs meet the following requirements:
+5 more criteria

Exclusion Criteria

•Women who are pregnant or nursing, or have fertility but refuse to take contraceptive measures;
•During the enrollment period, a serious active infection requiring antibiotic intravenous treatment occurred;
•Those who are allergic to test drugs;
•Presence of ≥2 grade neuropathy (CTCAE 5.0);
•Uncontrolled, symptomatic brain metastases or those with a history of difficult-to-control mental illness or severe intellectual or cognitive dysfunction;
•Suffering from active, known or suspected autoimmune diseases (including but not limited to: uveitis, enteritis, hepatitis, pituitary inflammation, nephritis, vasculitis, hyperthyroidism, hypothyroidism and the need for bronchodilators Treatment of asthma, etc.). Subjects with hypothyroidism who only need hormone replacement therapy and skin diseases that do not require systemic treatment (such as vitiligo, psoriasis, or hair loss) can be selected;
•Have been vaccinated or will be vaccinated with live vaccine within 30 days before the administration of Camrelizumab;
•Congestive heart failure, uncontrolled arrhythmia, myocardial infarction, unstable angina, stroke or transient ischemic attack within 6 months; or other patients who cannot tolerate surgery;
•Suffering from other malignant tumors within 5 years, except for fully treated cervical carcinoma in situ or squamous cell carcinoma of the skin, or basal cell carcinoma of the skin that has been basically controlled;
•Patients who cannot comply with the trial protocol or cannot cooperate with follow-up;
+5 more criteria

Key Dates

Start Date

August 1, 2020

Primary Completion Date

August 1, 2022

Completion Date

August 1, 2023

Last Updated

October 4, 2022

Conditions

Pancreatic CancerLiver Metastasis

Interventions

Camrelizumab

DRUG

Chemotherapy

DRUG

Ablation

PROCEDURE

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors

NCT05053971

Advanced Malignant Solid NeoplasmLocally Advanced Pancreatic Carcinoma+7 more

View study

RECRUITINGPHASE2

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

NCT04550494

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+29 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 4, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Trial of Camrelizumab Combined With Ablation and Chemotherapy in Patients With Pancreatic Cancer Liver Metastasis（SHR-1210-HLJ-009）

Inclusion Criteria

Exclusion Criteria

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Resilience and Equity in Aging, Cancer, and Health (REACH)

Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation

A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples